IMARA Inc. (IMRA)
$4.7
+0.16 (+3.52%)
Rating:
Recommendation:
-
| Symbol | IMRA |
|---|---|
| Price | $4.7 |
| Beta | 1.050 |
| Volume Avg. | 0.11M |
| Market Cap | 123.550M |
| Shares () | - |
| 52 Week Range | 0.974-5.261 |
| 1y Target Est | - |
| DCF Unlevered | IMRA DCF -> | |
|---|---|---|
| DCF Levered | IMRA LDCF -> | |
| ROE | -64.98% | Strong Sell |
| ROA | -76.16% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 3.17% | Neutral |
| P/E | - | |
| P/B | 2.16 | Strong Buy |
Latest IMRA news
About
Download (Excel)IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.